Cargando…
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
Sarcomas are a heterogeneous group of mesenchymal orphan cancers and new treatment alternatives beyond traditional chemotherapeutic regimes are much needed. So far, tumor mutation analysis has not led to significant treatment advances, and we have attempted to bypass this limitation by performing di...
Autores principales: | Grad, Iwona, Hanes, Robert, Ayuda-Durán, Pilar, Kuijjer, Marieke Lydia, Enserink, Jorrit M., Meza-Zepeda, Leonardo A., Myklebost, Ola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946228/ https://www.ncbi.nlm.nih.gov/pubmed/33690666 http://dx.doi.org/10.1371/journal.pone.0248140 |
Ejemplares similares
-
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
por: Hanes, Robert, et al.
Publicado: (2016) -
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019) -
screenwerk: a modular tool for the design and analysis of drug combination screens
por: Hanes, Robert, et al.
Publicado: (2022) -
Accurate 3-gene-signature for early diagnosis of liposarcoma progression
por: Serguienko, Anastassia, et al.
Publicado: (2020) -
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)